SAN MATEO, Calif., July 8 /PRNewswire/ -- After meeting on July 1st and 2nd an FDA advisory panel recommended that all new diabetes drugs should undergo trials to rule out cardiovascular risk. 85% of US cardiologists and 65% of US endocrinologists agree with this recommendation, according to AlphaDetail Inc., a leader in cardiovascular and metabolic primary market research and key opinion leader mapping solutions to the Global Life Sciences Industry.
On July 3rd AlphaDetail launched its latest AlphaPulse(TM) survey to
measure immediate physician awareness and reactions to the panel
recommendation. In a brief on-line survey of 52 cardiologists and 51
endocrinologists AlphaDetail found:
-- Unaided, about 40% of physicians mentioned CV risk associated with
diabetes medications as the most important development in diabetes
treatment from the past month.
-- When prompted, half of physicians indicated they had heard about the
FDA panel recommendation to require cardiovascular safety trials for
new diabetes medications -- only a day after the news was announced.
-- Although most physicians from both specialties support the
recommendation, twice as many cardiologists (33%) vs. endocrinologists
(16%) agree strongly with it.
-- However, 22% of endocrinologists disagree with the
recommendation primarily because they believe it would stifle
innovation and delay the availability of important new
-- Physicians disagree on the most appropriate implementation of the FDA
panel recommendation -- two CV safety trials vs. only one trial.
-- However, more physicians believe that the two trial
implementation is the most appropriate.
-- Even so, a segment of physicians (25% of cardiologists and 37% of
endocrinologists) would support prescribing a new diabetes therapy
|SOURCE AlphaDetail, Inc.|
Copyright©2008 PR Newswire.
All rights reserved